CTOs on the Move

Resilience Technology Corporation

www.resilience.com

 
Resilience is changing the way medicine is made – leveraging innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Robert Brown
Senior Director of Cyber Resilience Profile
Michael Good
Director Security Operations Profile
Brandy Duso
Director of Compliance and Risk Profile
Bill Reid
CISO and VP, Security and Privacy Profile
Chris Taylor
Senior Director Information Technology Profile

Funding

Resilience Technology Corporation raised $750M on 11/23/2020
Resilience Technology Corporation raised $625M on 06/06/2022

Similar Companies

NexBio

NexBio is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virent Energy Systems

Virent Energy Systems is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Revibe Technologies

Revibe Technologies is dedicated to helping children and adults overcome obstacles faced in the classroom and workplace by fusing psychology with technology. School psychologist Rich Brancaccio founded Revibe in 2013 to create a specialized tool to help kids overcome their difficulties by leveling the playing field through technology. Revibe is a wearable that leverages proprietary algorithms to help kids adults combat distraction through gentle vibration reminders.

Optimer Pharmaceuticals

Optimer Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genmab

Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.